

51st Annual VEITH Symposium, November 19-21, 2024

Value and Limitations of Statins and Non-Statins Lipid Lowering Agents in Patients with Carotid Artery Stenosis: Should They Be the Same of Different In Patients Undergoing Invasive Procedures

Kosmas I. Paraskevas, MD
 Department of Vascular Surgery, Red Cross Hospital, Athens, Greece

Conflicts of Interest: None

374 Paraskevas et al. JOURNAL OF VASCULAR SURGERY August 2007

Statins: An essential component in the management of carotid artery disease

Kosmas I. Paraskevas, MD, FASA,^a George Hamilton, MD, FRCS,^b and Dimitri P. Mikhailidis, MD, FFPM, FRCPath, FRCP,^c London, United Kingdom
 J Vasc Surg 2007;46:373-86

- Statins reduce carotid intima-media thickness progression rates
- Statins reduce TIA/stroke and MI/coronary event/death rates
- Statins improve perioperative stroke/death rates in patients undergoing CEA

110 The Open Cardiovascular Medicine Journal, 2008, 2, 110-114 Open Access

Statin Treatment, Carotid Atherosclerotic Plaque Macrophage Infiltration and Circulating Inflammatory Markers

Michael Koutouzis¹, Kosmas I. Paraskevas^{2*}, Loukianos S. Rallidis³, Calypso Barbatis⁴, Alexandros Nomikos⁵, Vasiliki Tzavara¹, Maria Tsopanomichalou¹, Christos Lioupis¹, Nikolaos Bessias, Vassilios Andrikopoulos², Dimitri P. Mikhailidis⁶ and Zenon S. Kyriakides¹

- Statins reduce carotid plaque inflammation
- Statins reduce platelet reactivity and deposition on carotid plaques
- Statins promote carotid plaque stability

112 Current Vascular Pharmacology, 2013, 11, 112-120

Perioperative/Periprocedural Effects of Statin Treatment for Patients Undergoing Vascular Surgery or Endovascular Procedures: An Update

Kosmas I. Paraskevas¹, Frank J. Veith², Christos D. Liapis³ and Dimitri P. Mikhailidis^{4*}

- Statins reduce TIA/stroke and MI/coronary event/death rates in CAS/CEA pts
- Statins improve perioperative stroke/death rates in pts undergoing CAS/CEA
- Statins improve renal function and reduce contrast-induced nephropathy rates

International Journal of Cardiology 220 (2016) xxx

Contents lists available at ScienceDirect
 International Journal of Cardiology
 Journal homepage: www.elsevier.com/locate/ijcard

Correspondence
 Statins induce regression of carotid artery stenosis: Fact or fiction?
 Kosmas I. Paraskevas^{a,*}, Dimitri P. Mikhailidis^b, Frank J. Veith^{c,d}

^a Northern Vascular Centre, Freeman Hospital, Newcastle upon Tyne, UK
^b Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London, UK
^c Division of Vascular Surgery, New York University Langone Medical Center, New York, USA
^d Division of Vascular Surgery, The Cleveland Clinic, Cleveland, USA

Statin induce regression of carotid artery stenosis

vs.

Statin reduce carotid artery stenosis progression rates

838 Paraskevas et al JOURNAL OF VASCULAR SURGERY March 2011

Optimal statin type and dosage for vascular patients

Kosmas I. Paraskevas, MD,¹ Dimitri P. Mikhailidis, MD,² and Frank J. Veith, MD, FACS,³ Athens, Greece; London, United Kingdom; and New York, NY

J Vasc Surg 2011;53:837-44

- Statins should not be discontinued perioperatively/periprocedurally
- Rosuvastatin/atorvastatin ≥ 20 mg/day is the optimal statin type & dosage
- Statin loading dose prior to an intervention (CAS / TCAR)

Vascular, Vol. 19 No. 3, pp. 117-120, 2011
© 2011 Royal Society of Medicine Press. All rights reserved.
ISSN: 1748-5381
DOI: 10.1258/vasc.2011.008008

Optimal contemporary management of symptomatic and asymptomatic carotid artery stenosis

Kosmas I Paraskevas¹, Dimitri P Mikhailidis², Wesley S Moor² and Frank J Veith³**

Angiology
1-9
© The Author(s) 2015
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/000319115624236
sagepub.com
SAGE

Definition of Best Medical Treatment in Asymptomatic and Symptomatic Carotid Artery Stenosis

Kosmas I. Paraskevas, MD, PhD¹, Dimitri P. Mikhailidis, MD, FPPM, FRCPath, FRCP², Frank J. Veith, MD, FACS^{3,4}, and J. David Spence, MD, FRCP, FAHA⁵

Current Vascular Pharmacology, 2011, 9, 351-354 351

Editorial

Carotid Intima-Media Thickness and Ezetimibe: The End of a Misunderstanding?

Kosmas I. Paraskevas¹, Frank J. Veith^{2,3} and Dimitri P. Mikhailidis^{3,4}

- Statin + Ezetimibe combination vs. Statin monotherapy
- Effects on carotid IMT progression rates
- Effects on cardiovascular events?

Paraskevas et al. Cholesterol, carotid stenosis and stroke

Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know

Kosmas I. Paraskevas¹, Frank J. Veith^{2,3}, Hans-Henning Eckstein⁴, Jean-Baptiste Ricco⁵, Dimitri P. Mikhailidis⁶

© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2020;8(19):1265 | <http://dx.doi.org/10.21037/atm.2020.02.176>

- LDL-C in high-risk ASCVD pts < 70 mg/dl
- LDL-C in very high-risk ASCVD pts < 55 mg/dl
- Combination of high-dose statin ± PCSK-9 inhibitors ± ezetimibe ± fibrate

AbuRahma et al Journal of Vascular Surgery

The Society for Vascular Surgery implementation document for management of extracranial cerebrovascular disease

Ali F. AbuRahma, MD,¹ Efthymios D. Avgerinos, MD, PhD,² Robert W. Chang, MD,³ R. Clement Darling III, MD,⁴ Audra A. Duncan, MD,⁵ Thomas L. Forbes, MD,⁶ Mahmoud B. Malas, MD, MHS,⁷ Bruce Alan Perler, MD, MBA,⁸ Richard J. Powell, MD,⁹ Caron B. Rockman, MD,¹⁰ and Wei Zhou, MD,¹¹ Charleston, WV; Pittsburgh, Pa; San Francisco and La Jolla, Calif; Albany and New York, NY; London and Toronto, Ontario, Canada; Baltimore, Md; Lebanon, NH; and Tucson, Ariz

Summary and recommendations

5. In patients with a prior history of stroke or TIA, we recommend statin therapy.
6. In patients without a prior history of cardiovascular disease, we recommend statins in the primary prevention of fatal and nonfatal strokes.
14. In patients undergoing CEA, we recommend statin therapy.
18. In patients undergoing CAS, we recommend statin use.

Reviews

Comparison of Recent Practice Guidelines for the Management of Patients With Asymptomatic Carotid Stenosis

Angiology
2020, Vol. 67(5), 1-8
© The Author(s) 2020
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/00031911201081914
sagepub.com
SAGE

Kosmas I. Paraskevas, MD¹, Dimitri P. Mikhailidis, MD, FPPM, FRCPath², Pier Luigi Antognani, MD, PhD, FIJA³, Enrico Ascher, MD, FACS⁴, Hedyeh Baradaran, MD⁵, Reinoud P.H. Bolkers, MD, PhD, EBIR⁶, Richard P. Cambria, MD, FACS⁷, Anthony J. Comerota, MD, FACS⁸, Alan Dardik, MD, PhD, FACS, DFSVS, FAHA⁹, Alun H. Davies, MA, DM, FRCS¹⁰, Hans-Henning Eckstein, MD, PhD, FEBVS¹¹, Gianluca Faggioli, MD, PhD¹², Jose Fernandes e Fernandes, MD, PhD, FACS, FRCS Eng, FESC, FEBVS¹³, Gustav Fraedrich, MD¹⁴, George Geroulakos, MD, PhD, FRCS¹⁵, Peter Gloviczki, MD¹⁶, Jonathan Golledge, MB, BChir, MA, MChir, FRCS, FRACS¹⁷, Ajay Gupta, MD, MS¹⁸, Mateja K. Jezovnik, MD, PhD¹⁹, Stavros K. Kakikos, MD, DM, MSc, PhD, RVT²⁰, Niki Katsiki, MSc, PhD, MD²¹, Michael Knoftach, MD, PhD²², M. Elaine Kwoi, PhD^{23,24}, Gaetano Lanza, MD, PhD²⁵, George S. Lavenson Jr., MD, FACS, RVT²⁶, Christos D. Liapis, MD, FRCS, FACS²⁷, Ian M. Loftus, BSc, MChB, MD, FRCS²⁸, Armando Mansilha, MD, PhD, FIJA, FEBVS^{29,30}, Antoine Millon, MD, PhD³¹, Andrew N. Nicolalides, MS, FRCS, PhD (Hons)³², Rodolfo Pini, MD, PhD³³, Pavel Poredos, MD, PhD³⁴, Robert M. Proczka, MD, PhD³⁴, Jean-Baptiste Ricco, MD, PhD, FEBVS³⁵, Thomas S. Riles, MD, FACS³⁶, Peter Arthur Ringled, MD³⁷, Tatjana Rundek, MD, PhD³⁸, Luca Saba, MD³⁹, Felix Schlaichatzki, MD⁴⁰, Mauro Silvestrini, MD⁴¹, Francesco Spinelli, MD⁴², Francesco Stilo, MD, PhD⁴³, Sherif Sultan, MD, FACS, FRCS, PhD⁴³, Jeejit S. Suri, PhD, MBA, FIEB, FAIME, FAJUH, FSVN, FAIVS⁴⁴, Alexei V. Svetlikov, MD, PhD⁴⁵, Clark J. Zeebregts, MD, PhD⁴⁶, and Seemant Chaturvedi, MD⁴⁷

Progress in Cardiovascular Diseases xxx (xxxx) 1-7

Contents lists available at ScienceDirect

Progress in Cardiovascular Diseases

Journal homepage: www.elsevier.com/locate/pcad

Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease

Kosmas I. Paraskevas^{a,*}, Peter Glaviczki^b, Pier Luigi Antignani^c, Anthony J. Comerota^d, Alan Dardik^e, Alun H. Davies^f, Hans-Henning Eckstein^g, Gianluca Faggioli^h, Jose Fernandes e Fernandesⁱ, Gustav Fraedrich^j, George Geroulakos^k, Jonathan Golledge^l, Ajay Gupta^m, Victor S. Gunevichⁿ, Arkadiusz Jawien^o, Matej K. Jezovnik^p, Stavros K. Kakkos^q, Michael Knoflach^r, Gaetano Lanza^s, Christos D. Liapis^t, Ian M. Loftus^u, Armando Mansilha^{v,w}, Andrew N. Nicolaides^x, Rodolfo Pini^y, Pavel Poredos^z, Robert M. Proczka^{aa}, Jean-Baptiste Ricco^{ab}, Tatjana Rundek^{ac}, Luca Saba^{ad}, Felix Schlachetki^{ae}, Mauro Silvestrini^{af}, Francesco Spinelli^{ag}, Francesco Stilo^{ah}, Jasjit S. Suri^{ai}, Alexei V. Svetlikov^{aj}, Clark J. Zebregs^{ak}, Seemant Chaturvedi^{al}, Frank J. Veith^{ak,al}, Dimitri P. Mikhailidis^{am}

Statin Side Effects

"LIPITOR"

Liver Effects
 Increased Blood Sugar
 Pain (Muscles)
 Impaired Memory
 Tiredness/Fatigue
 Other (Headaches, Nausea)
 Rhabdomyolysis

MEMORIC MONDAY

STATINS SIDE EFFECTS

H M G C O A R E D U C T A S E I N H I B I T O R

H EPATOTOXICITY

M YOPATHY MYALGIA MYOSITIS

G I UPSET DIARRHEA, VOMITING, DIARRHEA

C ATARACTS

R H ABDOMYOLYSIS

I NCREASED RISK OF DIABETES

© 2013 STATINSIDE.COM

PRO CON STATIN THERAPY OVER 50?

Will Routine Use of Statins After Age 50 Become as Common as Fluoridating Drinking Water? It Should!

by Jerry Palmer, MD

Journal of Negative Results in BioMedicine

Mini-review

The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst

Nusrat Shafiq¹, Samir Malhotra¹, L. Promila Pandhi¹ and Anil Grover²

Journal of the American Medical Association (2014), 311, 892-898

Available online at www.sciencedirect.com

ScienceDirect

Journal homepage: www.jnrb.online.com

REVIEW ARTICLE

Are statins really wonder drugs?

Harpreet Singh Grover, Shally Luthra^{*}, Shruti Maroo

Thank you for your attention!